文献速递垂体与肾上腺疾病

恶性嗜铬细胞瘤与副神经节瘤的预后:MAPP-Prono研究

Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

中位随访68个月,中位生存6.7年;

要点

  • 激素高分泌是恶性嗜铬细胞瘤/副神经节瘤总生存更差的独立预后因素。
  • 本研究未证实SDHB突变为主要预后参数。
  • 单因素分析中头颈部副神经节瘤、年龄<40岁、甲氧基肾上腺素类低于正常上限5倍及低增殖指数与较好生存相关。

核心结论

  • 本研究未证实SDHB突变是恶性嗜铬细胞瘤/副神经节瘤的主要预后参数,提示还有其他关键分子事件参与肿瘤进展。

研究设计与样本

  • 恶性诊断依据为诊断时颈-胸-腹-盆腔CT或MRI。

主要发现

  • 原发嗜铬细胞瘤占53%,肿瘤或激素相关症状分别占57%和58%,血浆或尿激素阳性占81%,SDHB突变占42%。
  • 转移部位包括骨64%、淋巴结40%、肺29%、肝26%;从初诊到恶性诊断平均43个月(范围0–614)。
  • 中位随访68个月,中位生存6.7年。
  • 单因素分析中较好生存与头颈部副神经节瘤、年龄<40岁、甲氧基肾上腺素类低于正常上限5倍及低增殖指数相关。

临床怎么用

  • 对恶性嗜铬细胞瘤/副神经节瘤患者应评估激素分泌水平,高分泌提示总生存预后更差。
  • SDHB突变不宜单独作为该人群的主要预后判断依据。

局限性

  • 本研究为回顾性多中心设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant pheochromocytoma and paraganglioma (MPP) are characterized by prognostic heterogeneity. Our objective was to look for prognostic parameters of overall survival (OS) in MPP patients. PATIENTS AND METHODS: Retrospective multicenter study of MPP characterized by a neck-thoraco-abdomino-pelvic CT or MRI at the time of malignancy diagnosis in European centers between 1998 and 2010. RESULTS: One hundred sixty-nine patients from 18 European centers were included. Main characteristics of patients with MPP were: primary pheochromocytoma in 53% of patients; tumor- or hormone-related symptoms in 57% or 58% of cases; positive plasma or urine hormones in 81% of patients; identification of a mutation in SDHB in 42% of cases. Metastatic sites included bone (64%), lymph node (40%), lung (29%), and liver (26%); mean time between initial and malignancy diagnosis was 43 months (range, 0 to 614). Median follow-up was 68 months and median survival 6.7 years. Using univariate analysis, better survival was associated with head and neck paraganglioma, age <40 years, metanephrines less than fivefold the upper limits of the normal range, and low proliferative index. In multivariate analysis, hypersecretion [hazard ratio 3.02 (1.65 to 5.55); P = 0.0004] was identified as an independent significant prognostic factor of worst OS. CONCLUSIONS: Our results do not confirm SDHB mutations as a major prognostic parameter in MPP and suggest additional key molecular events involved in MPP tumor progression. Aside from SDHB mutation, the biology of aggressive MPP remains to be understood.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hescot S, Curras-Freixes M, Deutschbein T, et al. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab. 2019. PMID: 30715419. doi:10.1210/jc.2018-01968

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。